Santarus takes hit on Dutch snub of Cosmo ulcerative colitis drug
This article was originally published in Scrip
Executive Summary
Italian drug maker Cosmo Pharmaceuticals got the boot from the Netherlands Medicines Evaluation Board (MEB) for Cortiment (budesonide with MMX technology) as a therapy for induction of remission in patients with active mild-to-moderate ulcerative colitis – an outcome that may potentially spell bad news for the firm's US partner Santarus, whose shares took a hit on 9 August.